DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

The clinical efficacy of tolterodine extended-release is maintained for 24 h in patients with overactive bladder.

Author(s): Dmochowski R(1), Kreder K, MacDiarmid S, Carlsson M, Guan Z.

Affiliation(s): Author information: (1)Department of Urology, Vanderbilt University Medical Center, Nashville, TN 37232, USA. roger.dmochowski@vanderbilt.edu

Publication date & source: 2007, BJU Int. , 100(1):107-10

OBJECTIVE: To assess the 24-h efficacy of tolterodine extended-release (ER) in patients with overactive bladder (OAB) and urgency urinary incontinence (UUI). PATIENTS AND METHODS: We conducted a post hoc analysis of a 12-week, placebo-controlled trial of tolterodine-ER in patients with frequency (> or =8 voids/24 h) and UUI (> or=5 episodes/week) for > or = 6 months. Seven-day bladder diaries were used to record diary endpoints; 24-h diary data were stratified by 6-h periods beginning at midnight. RESULTS: Compared with placebo (508 patients), tolterodine-ER (507 patients) significantly and consistently increased volume voided per void and reduced UUI episodes and micturition frequency during each interval. CONCLUSIONS: These results indicate that tolterodine-ER maintained clinical efficacy over 24 h and should be effective for OAB symptoms without regard to whether symptoms occur during the day or at night.

Page last updated: 2015-08-10

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017